Clinical Trial

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Name: Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC — clinical trial record (NCT05608200)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2022-11-02.

Trial Details

NCT Number	NCT05608200
Lead Sponsor	Second Affiliated Hospital of Guangzhou Medical University
Conditions	Hepatocellular Carcinoma Non-resectable
Enrollment	427 participants
Start Date	2022-11-02
Primary Completion	2026-10-31 (estimated)
Study Completion	2026-10-31 (estimated)
Updated on ClinicalTrials.gov	2023-05-31